Trial Profile

Phase I/II study of URLC10-177 [URLC10 peptide vaccine] and TTK-567 [cancer vaccines], novel tumor specific epitope peptides restricted to HLA-A 2402 derived from tumor associated antigens, combined with CpG7909 [agatolimod], a TLR9 agonist, in patients with advanced or recurrent esophageal cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cancer vaccines (Primary) ; URLC10 peptide vaccine (Primary) ; Agatolimod; Montanide ISA-51
Indications Oesophageal cancer
Focus Adverse reactions; Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com